November 2008 Br J Cardiol 2008;15:284–8
BJCardio editorial team
JUPITER shows large cardiovascular risk reduction in primary prevention The eagerly awaited landmark JUPITER trial shows that the treatment of apparently healthy patients – who had low levels of low-density lipoprotein (LDL) cholesterol but elevated C-reactive-protein (CRP) levels – with rosuvastatin cuts their risk of cardiovascular disease morbidity and mortality by around 50%. The results were the first late-breaking trial data reported here at the AHA 2008 Scientific Sessions and were also published in the New England Journal of Medicine (N Engl J Med 2008; 359: 2195-207). JUPITER was designed as a four-year study but was stopped in
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits